OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in ...

Investing.com -- OSR Holdings Inc (NASDAQ:OSRH) stock surged 30.5% on Friday after the company announced its subsidiary Vaximm AG had entered a non-binding term sheet with BCM Europe AG to explore a ...

OSR Holdings (OSRH) announced that Vaximm AG, an OSR company, has entered into a non-binding term sheet with BCM Europe AG, a Swiss-based life ...

The importance of minority-interest remeasurement has expanded as joint venture and platform-licensing models become more common in biotech. For investors, such metrics provide an improved lens for ...

Researchers at UMC Utrecht developed two first-in-class antibodies that block FcγRI, offering new options to reduce ...

Summary • OSR Holdings, Inc. (OSRH) stock has surged 52.35% to $0.6947, with over 49 million shares traded today.• The rise ...

Barré syndrome market is poised for substantial growth, fueled by advancements in treatment options, including intravenous immunoglobulin (IVIg), plasmapheresis, and emerging immunotherapies.

As pharmaceutical giants increasingly look outside their walls for breakthrough innovations, the licensing model has become ...

In this episode, Bertrand Tombal discusses the latest updates in genitourinary cancers presented at ESMO 2025.

Market OverviewThe global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a value of USD 294.4 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 8 ...

The FDA will now allow biotechs to ask agency staff for “quick clarifications” via email. Elsewhere, Novartis hiked guidance for two top drugs and a startup nearing “unicorn” status secured a ...

Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...